Loading
Antibodies against LAG-3, another brake on tired T cells; relatlimab plus nivolumab became the first approved LAG-3 combination for melanoma in 2022.
Lymphocyte activation gene 3 (LAG-3) is a checkpoint expressed on exhausted T cells that binds MHC class II and fibrinogen-like protein 1. The fixed-dose combination of relatlimab and nivolumab (Opdualag) roughly doubled progression-free survival compared with nivolumab alone in untreated advanced melanoma in the RELATIVITY-047 trial and was approved by the FDA in 2022, the first new checkpoint class since PD-1. Trials in lung, colorectal and other cancers continue, with mixed results.
Antibodies block LAG-3 binding to its ligands so exhausted T cells regain function, usually combined with PD-1 blockade because the two pathways co-inhibit.
Favezelimab is Merck's LAG-3 antibody, tested with pembrolizumab in phase 3 trials in colorectal cancer and classical Hodgkin lymphoma; the colorectal trial did not succeed.
Query for this technology: (TITLE:"LAG-3 blockade" OR ABSTRACT:"LAG-3 blockade") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LAG-3 blockade, not a curated reading list.
Shares Advanced melanoma (unresectable stage III and stage IV), Nivolumab, Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Nivolumab, Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Nivolumab, Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Nivolumab, Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Nivolumab, Melanoma.
Shares LAG-3, Advanced melanoma (unresectable stage III and stage IV), Nivolumab, Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Nivolumab, Melanoma.